Nasdaq:US$15.34 (-0.14) | HKEX:HK$23.60 (-0.60) | AIM:£2.28 (+0.07)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer